{"entity":{"id":"nct07672236","kind":"trial","name":"A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.","aka":[],"tldr":"A phase 3 trial of BupiZenge 25 mg in advanced solid tumours, run by OncoZenge AB, now recruiting.","summary":"A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. is a phase 3 interventional study registered as NCT07672236 by OncoZenge AB, with 150 participants planned, started 2026-07-07 and due to reach its primary completion in 2026-12-23. Interventions recorded: BupiZenge 25 mg and Lidocaine viscous 2%.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07672236","url":"https://clinicaltrials.gov/study/NCT07672236"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07672236","phase":"3","setting":"A Randomized, Open-label, Phase III Trial to Assess the Efficacy and Safety of BupiZenge Compared to Lidocaine for Pain Associated With Oral Mucositis in Head and Neck Cancer","sponsor":"OncoZenge AB","enrolled":150,"outcomes":[]},"route":"/trials/nct07672236/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}